Why Is ASCENDIS PHARMA A/S (ASND) Stock Up Today?

Why ASND stock is up today

Ascendis Pharma A/S stock rose 6.10% to $263.04 in early trading, driven by the company's settlement of a global patent dispute with BioMarin Pharmaceutical. The resolution of the litigation over the drug Yuviwel, announced Sunday, removed a significant overhang and prompted analyst activity across several firms. The stock has climbed to a new 52-week high, reflecting investor optimism about the outcome.

What Happened

Ascendis Pharma and BioMarin reached a global settlement and license agreement, ending a legal dispute over the drug Yuviwel, which treats achondroplasia. The settlement was described by analysts as a clean overhang lift, with no changes to existing ratings. Jefferies raised its price target for BioMarin, while H.C. Wainwright and several other firms adjusted their price targets for Ascendis, reducing them slightly. BofA, Jefferies, and Stifel all maintained Buy ratings but trimmed their price targets to $304, $330, and $326 respectively. The stock's sharp intraday rise of 7% and a closing gain of 8.0% underscore the market's positive reception to the news.

What The Data Shows

The stock has gained 4.2% over the last eight sessions, rising from $254.81 to $265.60. On August 31, it printed eight fresh 52-week highs. Insider transactions show Jean Jacques Bienaime, a director, purchased shares on August 14. Over the last 90 days, insiders have made one buy totaling $493K, with no sell activity. The stock's fundamentals include a market cap of $16.3B, a P/E of 18.5, and trailing 12-month revenue growth of 113.4%. With a beta of 0.49, the stock is less volatile than the broader market.

What To Watch

Investors should monitor the stock's performance in the coming weeks as analysts refine their outlooks. No earnings date is currently scheduled, but coverage breadth and price target adjustments will be key indicators of market sentiment.